Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2015

View Archived Issues

University of California, Oakland and WARF patent bacterial DNA gyrase inhibitors

First patient dosed in phase II trial of tipifarnib in patients with HRAS-mutant urothelial cancer

HTIT licenses marketing rights to Oramed's oral insulin in China

Combination of PI3K/Akt and JAK/PIM inhibitors shows synergistic antitumor effect

First patient dosed in phase II study of N-91115 for cystic fibrosis

FDA clears IND application for SB-FIX

Repros Therapeutics receives FDA complete response letter for enclomiphene

Amcure awarded research grant from German Ministry of Education

Adding DNA-damaging properties to PARP inhibitor enhances potency

Marathon Pharmaceuticals launches expanded access program for deflazacort in DMD

Active Biotech patents S100A9 inhibitors

Celon Pharma announces PDE10A inhibitors

Medshine Discovery and North China Pharmaceutical report FXa inhibitors

Actelion Pharmaceuticals introduces antibacterial compounds

University of Illinois patents amphotericin B epimer

NINDS grant supports Hillhurst's development of HBI-002 for acute cerebral injury

Novo Nordisk licenses antibodies targeting insulin receptor from XOMA

Mylan outlines plans for antiretroviral treatment TLE-400

BioCellChallenge reports in vivo findings confirming efficacy of ImmunoCellin technology

First-in-class FGFR inhibitor demonstrates FGFR subtype selectivity

Maximal virologic suppression reported at 1 year in phase IIb extension study of PRO-140

MabVax files IND application for anticancer antibody

Topline data from phase III TELECAST study of telotristat etiprate in carcinoid syndrome

BMS and National Comprehensive Cancer Network collaborate to study PD-L1 expression

MPP and University of Liverpool collaborate to develop nanoformulated antiretrovirals